Current Gene Therapy

Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard
Nantes
France

Back

Targeted Genome Editing Tools for Disease Modeling and Gene Therapy

Author(s): Mi Cai and Yi Yang

Affiliation: Novartis Institutes of Biomedical Research Inc., 100 Technology Square, Cambridge, MA 02139, USA.

Keywords: Zinc finger nucleases, TALENs, CRISPR, disease modeling, gene therapy, review.

Abstract:

The development of custom-designed nucleases (CDNs), including zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), has made it possible to perform precise genetic engineering in many cell types and species. More recently, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system has been successfully employed for genome editing. These RNA-guided DNA endonucleases are shown to be more efficient and flexible than CDNs and hold great potential for applications in both biological studies and medicine. Here, we review the progress that has been made for all three genome editing technologies in modifying both cells and model organisms, compare important aspects of each approach, and summarize the applications of these tools in disease modeling and gene therapy. In the end, we discuss future prospects of the field.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 14
ISSUE: 1
Page: [2 - 9]
Pages: 8
DOI: 10.2174/156652321402140318165450